STRATEGIES AND CHALLENGES IN METHOD DEVELOPMENT AND VALIDATION FOR THE ABSOLUTE QUANTIFICATION OF ENDOGENOUS BIOMARKER METABOLITES USING LIQUID CHROMATOGRAPHY‐TANDEM MASS SPECTROMETRY
Metabolomics is a dynamically evolving field, with a major application in identifying biomarkers for drug development and personalized medicine. Numerous metabolomic studies have identified endogenous metabolites that, in principle, are eligible for translation to clinical practice. However, few met...
Uloženo v:
| Vydáno v: | Mass spectrometry reviews Ročník 40; číslo 1; s. 31 - 52 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Wiley Subscription Services, Inc
01.01.2021
|
| Témata: | |
| ISSN: | 0277-7037, 1098-2787, 1098-2787 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Metabolomics is a dynamically evolving field, with a major application in identifying biomarkers for drug development and personalized medicine. Numerous metabolomic studies have identified endogenous metabolites that, in principle, are eligible for translation to clinical practice. However, few metabolomic‐derived biomarker candidates have been qualified by regulatory bodies for clinical applications. Such interruption in the biomarker qualification process can be largely attributed to various reasons including inappropriate study design and inadequate data to support the clinical utility of the biomarkers. In addition, the lack of robust assays for the routine quantification of candidate biomarkers has been suggested as a potential bottleneck in the biomarker qualification process. In fact, the nature of the endogenous metabolites precludes the application of the current validation guidelines for bioanalytical methods. As a result, there have been individual efforts in modifying existing guidelines and/or developing alternative approaches to facilitate method validation. In this review, three main challenges for method development and validation for endogenous metabolites are discussed, namely matrix effects evaluation, alternative analyte‐free matrices, and the choice of internal standards (ISs). Some studies have modified the equations described by the European Medicines Agency for the evaluation of matrix effects. However, alternative strategies were also described; for instance, calibration curves can be generated in solvents and in biological samples and the slopes can be compared through ratios, relative standard deviation, or a modified Stufour suggested approaches while quantifying mainly endogenous metabolitesdent t‐test. ISs, on the contrary, are diverse; in which seven different possible types, used in metabolomics‐based studies, were identified in the literature. Each type has its advantages and limitations; however, isotope‐labeled ISs and ISs created through isotope derivatization show superior performance. Finally, alternative matrices have been described and tested during method development and validation for the quantification of endogenous entities. These alternatives are discussed in detail, highlighting their advantages and shortcomings. The goal of this review is to compare, apprise, and debate current knowledge and practices in order to aid researchers and clinical scientists in developing robust assays needed during the qualification process of candidate metabolite biomarkers. © 2019 John Wiley & Sons Ltd. Mass Spec Rev |
|---|---|
| AbstractList | Metabolomics is a dynamically evolving field, with a major application in identifying biomarkers for drug development and personalized medicine. Numerous metabolomic studies have identified endogenous metabolites that, in principle, are eligible for translation to clinical practice. However, few metabolomic-derived biomarker candidates have been qualified by regulatory bodies for clinical applications. Such interruption in the biomarker qualification process can be largely attributed to various reasons including inappropriate study design and inadequate data to support the clinical utility of the biomarkers. In addition, the lack of robust assays for the routine quantification of candidate biomarkers has been suggested as a potential bottleneck in the biomarker qualification process. In fact, the nature of the endogenous metabolites precludes the application of the current validation guidelines for bioanalytical methods. As a result, there have been individual efforts in modifying existing guidelines and/or developing alternative approaches to facilitate method validation. In this review, three main challenges for method development and validation for endogenous metabolites are discussed, namely matrix effects evaluation, alternative analyte-free matrices, and the choice of internal standards (ISs). Some studies have modified the equations described by the European Medicines Agency for the evaluation of matrix effects. However, alternative strategies were also described; for instance, calibration curves can be generated in solvents and in biological samples and the slopes can be compared through ratios, relative standard deviation, or a modified Stufour suggested approaches while quantifying mainly endogenous metabolitesdent t-test. ISs, on the contrary, are diverse; in which seven different possible types, used in metabolomics-based studies, were identified in the literature. Each type has its advantages and limitations; however, isotope-labeled ISs and ISs created through isotope derivatization show superior performance. Finally, alternative matrices have been described and tested during method development and validation for the quantification of endogenous entities. These alternatives are discussed in detail, highlighting their advantages and shortcomings. The goal of this review is to compare, apprise, and debate current knowledge and practices in order to aid researchers and clinical scientists in developing robust assays needed during the qualification process of candidate metabolite biomarkers. © 2019 John Wiley & Sons Ltd. Mass Spec Rev.Metabolomics is a dynamically evolving field, with a major application in identifying biomarkers for drug development and personalized medicine. Numerous metabolomic studies have identified endogenous metabolites that, in principle, are eligible for translation to clinical practice. However, few metabolomic-derived biomarker candidates have been qualified by regulatory bodies for clinical applications. Such interruption in the biomarker qualification process can be largely attributed to various reasons including inappropriate study design and inadequate data to support the clinical utility of the biomarkers. In addition, the lack of robust assays for the routine quantification of candidate biomarkers has been suggested as a potential bottleneck in the biomarker qualification process. In fact, the nature of the endogenous metabolites precludes the application of the current validation guidelines for bioanalytical methods. As a result, there have been individual efforts in modifying existing guidelines and/or developing alternative approaches to facilitate method validation. In this review, three main challenges for method development and validation for endogenous metabolites are discussed, namely matrix effects evaluation, alternative analyte-free matrices, and the choice of internal standards (ISs). Some studies have modified the equations described by the European Medicines Agency for the evaluation of matrix effects. However, alternative strategies were also described; for instance, calibration curves can be generated in solvents and in biological samples and the slopes can be compared through ratios, relative standard deviation, or a modified Stufour suggested approaches while quantifying mainly endogenous metabolitesdent t-test. ISs, on the contrary, are diverse; in which seven different possible types, used in metabolomics-based studies, were identified in the literature. Each type has its advantages and limitations; however, isotope-labeled ISs and ISs created through isotope derivatization show superior performance. Finally, alternative matrices have been described and tested during method development and validation for the quantification of endogenous entities. These alternatives are discussed in detail, highlighting their advantages and shortcomings. The goal of this review is to compare, apprise, and debate current knowledge and practices in order to aid researchers and clinical scientists in developing robust assays needed during the qualification process of candidate metabolite biomarkers. © 2019 John Wiley & Sons Ltd. Mass Spec Rev. Metabolomics is a dynamically evolving field, with a major application in identifying biomarkers for drug development and personalized medicine. Numerous metabolomic studies have identified endogenous metabolites that, in principle, are eligible for translation to clinical practice. However, few metabolomic‐derived biomarker candidates have been qualified by regulatory bodies for clinical applications. Such interruption in the biomarker qualification process can be largely attributed to various reasons including inappropriate study design and inadequate data to support the clinical utility of the biomarkers. In addition, the lack of robust assays for the routine quantification of candidate biomarkers has been suggested as a potential bottleneck in the biomarker qualification process. In fact, the nature of the endogenous metabolites precludes the application of the current validation guidelines for bioanalytical methods. As a result, there have been individual efforts in modifying existing guidelines and/or developing alternative approaches to facilitate method validation. In this review, three main challenges for method development and validation for endogenous metabolites are discussed, namely matrix effects evaluation, alternative analyte‐free matrices, and the choice of internal standards (ISs). Some studies have modified the equations described by the European Medicines Agency for the evaluation of matrix effects. However, alternative strategies were also described; for instance, calibration curves can be generated in solvents and in biological samples and the slopes can be compared through ratios, relative standard deviation, or a modified Stufour suggested approaches while quantifying mainly endogenous metabolitesdent t‐ test. ISs, on the contrary, are diverse; in which seven different possible types, used in metabolomics‐based studies, were identified in the literature. Each type has its advantages and limitations; however, isotope‐labeled ISs and ISs created through isotope derivatization show superior performance. Finally, alternative matrices have been described and tested during method development and validation for the quantification of endogenous entities. These alternatives are discussed in detail, highlighting their advantages and shortcomings. The goal of this review is to compare, apprise, and debate current knowledge and practices in order to aid researchers and clinical scientists in developing robust assays needed during the qualification process of candidate metabolite biomarkers. © 2019 John Wiley & Sons Ltd. Mass Spec Rev Metabolomics is a dynamically evolving field, with a major application in identifying biomarkers for drug development and personalized medicine. Numerous metabolomic studies have identified endogenous metabolites that, in principle, are eligible for translation to clinical practice. However, few metabolomic-derived biomarker candidates have been qualified by regulatory bodies for clinical applications. Such interruption in the biomarker qualification process can be largely attributed to various reasons including inappropriate study design and inadequate data to support the clinical utility of the biomarkers. In addition, the lack of robust assays for the routine quantification of candidate biomarkers has been suggested as a potential bottleneck in the biomarker qualification process. In fact, the nature of the endogenous metabolites precludes the application of the current validation guidelines for bioanalytical methods. As a result, there have been individual efforts in modifying existing guidelines and/or developing alternative approaches to facilitate method validation. In this review, three main challenges for method development and validation for endogenous metabolites are discussed, namely matrix effects evaluation, alternative analyte-free matrices, and the choice of internal standards (ISs). Some studies have modified the equations described by the European Medicines Agency for the evaluation of matrix effects. However, alternative strategies were also described; for instance, calibration curves can be generated in solvents and in biological samples and the slopes can be compared through ratios, relative standard deviation, or a modified Stufour suggested approaches while quantifying mainly endogenous metabolitesdent t-test. ISs, on the contrary, are diverse; in which seven different possible types, used in metabolomics-based studies, were identified in the literature. Each type has its advantages and limitations; however, isotope-labeled ISs and ISs created through isotope derivatization show superior performance. Finally, alternative matrices have been described and tested during method development and validation for the quantification of endogenous entities. These alternatives are discussed in detail, highlighting their advantages and shortcomings. The goal of this review is to compare, apprise, and debate current knowledge and practices in order to aid researchers and clinical scientists in developing robust assays needed during the qualification process of candidate metabolite biomarkers. © 2019 John Wiley & Sons Ltd. Mass Spec Rev. |
| Author | El‐Aneed, Anas Khamis, Mona M. Adamko, Darryl J. |
| Author_xml | – sequence: 1 givenname: Mona M. surname: Khamis fullname: Khamis, Mona M. organization: University of Saskatchewan – sequence: 2 givenname: Darryl J. surname: Adamko fullname: Adamko, Darryl J. organization: University of Saskatchewan – sequence: 3 givenname: Anas surname: El‐Aneed fullname: El‐Aneed, Anas email: anas.el-aneed@usask.ca organization: University of Saskatchewan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31617245$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1u2zAQhYkiReOkXfQCBYFu2oUSkjJFaUlbtExUFh2JCpCVoB8KUGBbqWSjyK5H6HV6nZ6kdJx2EaBdDQbzzXuDeRfgbNfvDADvMbrCCJHrbTleEewh9gpMMAp8hzCfnYEJIow5DLnsHFyM4z1CGFOM34BzF3uYkSmdgJ-ZTrkWkRQZ5EkI50sexyKJbCsTuBJ6qUIYilsRq_VKJPoJuuWxDLmWKoELlUK9FJDPMhXnWsCbnCdaLuT8NFcLKJJQRSJReQZnUq14-kWkR2U-U7HU1ijPZBLBWN7k8nhAahmtopSvl3e_vv_Q1lGs4IpnGczWYq7tXOj07i143Zab0bx7rpcgXwg9Xzqxiqx77NQudZljKEFeW9aoaWrjEoJZVdPGDVpU-oayOqhQS5uKosB-EqG2pKZpLU3o1GDfq9xL8Omk-zD0Xw9m3BfbbqzNZlPuTH8YC-IijxAUYGrRjy_Q-_4w7Ox1BZl6ge9OA59Z6sMzdai2pikehm5bDo_Fn1As8PkE1EM_joNp_yIYFcfACxt48RS4Za9fsHW3L_ddv9sPZbf538a3bmMe_y1d2I-fNn4Db5Guow |
| CitedBy_id | crossref_primary_10_1016_j_jfca_2023_105347 crossref_primary_10_1016_j_jpha_2025_101289 crossref_primary_10_1016_j_saa_2024_123842 crossref_primary_10_1016_j_talanta_2023_124981 crossref_primary_10_1016_j_biotechadv_2025_108652 crossref_primary_10_1016_j_jhazmat_2021_128116 crossref_primary_10_1002_mas_21907 crossref_primary_10_3390_molecules27238413 crossref_primary_10_1002_jssc_70147 crossref_primary_10_1016_j_microc_2024_111845 crossref_primary_10_3390_molecules28186526 crossref_primary_10_1080_10408347_2022_2035210 crossref_primary_10_3390_biom13020383 crossref_primary_10_1016_j_jpba_2022_114775 crossref_primary_10_3390_metabo10050196 crossref_primary_10_3390_metabo13070844 crossref_primary_10_1016_j_aca_2021_339401 crossref_primary_10_3389_fcell_2020_00344 crossref_primary_10_3390_molecules26051402 crossref_primary_10_3390_pharmaceutics12121188 crossref_primary_10_1016_j_cej_2025_168145 crossref_primary_10_1016_j_jchromb_2021_123001 crossref_primary_10_1016_j_talanta_2024_127041 crossref_primary_10_3762_bjoc_18_153 crossref_primary_10_1002_mas_21635 crossref_primary_10_1016_j_chroma_2022_463261 crossref_primary_10_3389_fmolb_2023_1120376 crossref_primary_10_1186_s43094_023_00537_6 crossref_primary_10_1016_j_chroma_2021_462590 crossref_primary_10_1016_j_chroma_2023_464173 crossref_primary_10_1042_BCJ20210534 crossref_primary_10_4155_bio_2023_0209 crossref_primary_10_1002_anie_202409446 crossref_primary_10_1016_j_jpba_2023_115785 crossref_primary_10_1016_j_ebiom_2023_104627 crossref_primary_10_1016_j_talanta_2021_122919 crossref_primary_10_1002_ange_202409446 crossref_primary_10_1515_cclm_2020_0517 crossref_primary_10_1016_j_plipres_2021_101145 crossref_primary_10_1016_j_jpba_2022_114886 crossref_primary_10_1016_j_jpba_2023_115416 crossref_primary_10_1002_ansa_202400007 crossref_primary_10_1016_j_jchromb_2023_123778 crossref_primary_10_1016_j_trac_2023_117022 crossref_primary_10_1016_j_jchromb_2021_123010 crossref_primary_10_3389_fpsyt_2020_00432 crossref_primary_10_1016_j_microc_2025_113063 |
| Cites_doi | 10.1373/clinchem.2003.025478 10.1016/j.aca.2013.07.045 10.1016/j.cca.2015.04.005 10.1007/s00216-011-5439-8 10.1074/jbc.R111.238691 10.1016/j.aca.2017.08.007 10.1007/s00726-016-2212-5 10.1258/acb.2010.009270 10.1007/s00467-008-0756-7 10.1007/s11306-007-0091-1 10.1002/bmc.703 10.1373/clinchem.2004.039701 10.1039/c0mb00110d 10.1021/ac3025625 10.1021/ac900166a 10.1016/j.jpba.2015.02.040 10.1093/nar/gkn810 10.1002/bmc.329 10.1016/j.jchromb.2006.02.016 10.1021/ac060920l 10.1016/j.jpba.2016.06.017 10.1373/49.7.1041 10.2174/1874467211205020301 10.1016/j.talanta.2011.01.003 10.1016/j.chroma.2010.11.047 10.1002/mas.21455 10.1016/j.jpba.2012.04.018 10.1016/j.trac.2009.12.003 10.1002/rcm.1400 10.1016/j.jchromb.2009.09.038 10.1002/mas.20097 10.1002/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO;2-0 10.1038/srep21433 10.1002/rcm.876 10.1002/mas.20108 10.1016/j.chroma.2013.03.072 10.1016/S0378-4347(01)00552-7 10.1016/j.aca.2009.06.033 10.1074/mcp.M111.016006 10.1093/nar/gks1065 10.1021/ac050697c 10.1016/j.aca.2010.10.035 10.1016/j.cca.2011.09.007 10.1016/j.jpba.2006.09.030 10.1016/j.cca.2008.10.014 10.1016/j.trac.2011.08.009 10.1016/j.clinbiochem.2004.11.007 10.1016/j.aca.2013.06.044 10.1039/B906712B 10.1002/rcm.4459 10.1021/ac049746w 10.1038/nature07762 10.1016/j.jsbmb.2013.06.014 10.1016/j.jaci.2015.05.022 10.1002/rcm.1268 10.1021/ac5023315 10.1002/anie.200905579 10.1016/j.cca.2009.09.003 10.1021/ac020361s 10.1158/1055-9965.EPI-08-0355 10.1007/s00726-015-2076-0 10.1016/j.foodchem.2011.10.064 10.1016/j.aca.2008.07.036 10.1021/ac034505u 10.1016/j.jpba.2010.01.016 10.1007/978-1-4614-3828-1 10.1016/S0021-9673(01)01429-7 10.1002/mas.20316 10.1016/j.jchromb.2014.09.032 10.1016/j.chroma.2015.12.031 10.1002/0471142727.mb3002s98 10.1016/j.jchromb.2013.10.005 10.1016/j.jchromb.2010.03.035 10.4155/bio.12.218 10.1002/mas.20306 10.1016/j.cca.2009.11.003 10.1016/j.jpba.2006.08.010 10.1007/s11095-005-9045-3 10.1016/j.trac.2008.09.002 10.1016/j.chroma.2009.11.060 10.1016/j.jpba.2011.05.009 10.1016/j.chroma.2013.09.085 10.1002/rcm.2640 10.1155/2002/212987 10.1016/j.jchromb.2009.01.007 10.1007/s00216-018-1205-5 10.1021/acs.analchem.6b02967 10.1021/ac1019914 10.1016/j.jchromb.2007.12.011 10.1007/s00204-010-0609-6 10.2337/db13-0570 10.1016/j.jsbmb.2004.10.015 10.1007/s11306-018-1418-9 10.1016/j.ab.2007.03.018 10.1002/rcm.1243 10.1007/s11306-011-0342-z 10.1007/s00216-012-6375-y 10.1016/j.jchromb.2009.08.019 10.1007/s11095-005-2495-9 10.1002/rcm.1112 10.1002/rcm.1790 10.2217/bmm.09.81 10.1016/j.jchromb.2019.05.021 10.1002/rcm.617 10.2217/14622416.7.7.1095 10.1371/journal.pmed.0020124 10.1021/ja036006g 10.1378/chest.11-2028 10.1128/AEM.03595-14 10.1016/j.chroma.2011.10.081 10.1002/jms.3536 10.4103/2229-4708.72226 10.1016/j.jpba.2013.06.032 10.1016/S0003-2670(03)00463-X 10.1667/RR1703.1 10.1016/j.chroma.2016.02.009 10.1002/rcm.1530 10.1002/rcm.3755 10.1002/mas.20298 10.1002/rcm.2787 10.1039/b209521c 10.1039/a805224g 10.1016/j.aca.2012.05.006 |
| ContentType | Journal Article |
| Copyright | 2019 John Wiley & Sons Ltd. 2020 John Wiley & Sons Ltd. |
| Copyright_xml | – notice: 2019 John Wiley & Sons Ltd. – notice: 2020 John Wiley & Sons Ltd. |
| DBID | AAYXX CITATION NPM K9. 7X8 |
| DOI | 10.1002/mas.21607 |
| DatabaseName | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef ProQuest Health & Medical Complete (Alumni) PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Physics |
| EISSN | 1098-2787 |
| EndPage | 52 |
| ExternalDocumentID | 31617245 10_1002_mas_21607 MAS21607 |
| Genre | reviewArticle Journal Article Review |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AAHQN AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABIJN ABJNI ABPVW ABTAH ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AQPKS ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM DU5 EBD EBS EJD F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LH5 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR RNS ROL RWI RX1 RYL SAMSI SUPJJ TN5 UB1 V2E W8V W99 WBFHL WBKPD WH7 WIB WIH WIK WJL WOHZO WQJ WRC WRJ WXSBR WYISQ XG1 XPP XV2 ZY4 ZZTAW ~02 ~IA ~KM ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION O8X NPM K9. 7X8 |
| ID | FETCH-LOGICAL-c3537-e5206fac0ddce32217bc5d39f0a8e57c9b0f5db50900200fa5edfc0d254e186b3 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 59 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000490133000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0277-7037 1098-2787 |
| IngestDate | Fri Jul 11 13:08:33 EDT 2025 Sat Nov 29 14:33:26 EST 2025 Thu Apr 03 07:04:40 EDT 2025 Sat Nov 29 07:05:34 EST 2025 Tue Nov 18 21:48:56 EST 2025 Wed Jan 22 16:30:55 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | LC-MS/MS endogenous biomarkers metabolomics blank matrix internal standards validation |
| Language | English |
| License | 2019 John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3537-e5206fac0ddce32217bc5d39f0a8e57c9b0f5db50900200fa5edfc0d254e186b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| PMID | 31617245 |
| PQID | 2469834987 |
| PQPubID | 1016389 |
| PageCount | 22 |
| ParticipantIDs | proquest_miscellaneous_2306220915 proquest_journals_2469834987 pubmed_primary_31617245 crossref_primary_10_1002_mas_21607 crossref_citationtrail_10_1002_mas_21607 wiley_primary_10_1002_mas_21607_MAS21607 |
| PublicationCentury | 2000 |
| PublicationDate | January/February 2021 2021-01-00 20210101 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: January/February 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Mass spectrometry reviews |
| PublicationTitleAlternate | Mass Spectrom Rev |
| PublicationYear | 2021 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | e_1_2_8_1_36_1 e_1_2_8_1_13_1 e_1_2_8_1_55_1 e_1_2_8_1_32_1 Lee JW (e_1_2_8_1_58_1) 2003; 132 e_1_2_8_1_51_1 e_1_2_8_1_70_1 e_1_2_8_1_124_1 e_1_2_8_1_101_1 e_1_2_8_1_105_1 e_1_2_8_1_128_1 e_1_2_8_1_81_1 e_1_2_8_1_85_1 e_1_2_8_1_89_1 e_1_2_8_1_120_1 e_1_2_8_1_29_1 e_1_2_8_1_48_1 e_1_2_8_1_47_1 e_1_2_8_1_24_1 e_1_2_8_1_66_1 e_1_2_8_1_43_1 e_1_2_8_1_20_1 e_1_2_8_1_62_1 e_1_2_8_1_109_1 e_1_2_8_1_112_1 e_1_2_8_1_135_1 e_1_2_8_1_3_1 e_1_2_8_1_116_1 e_1_2_8_1_7_1 e_1_2_8_1_93_1 e_1_2_8_1_74_1 e_1_2_8_1_97_1 e_1_2_8_1_131_1 e_1_2_8_1_17_1 e_1_2_8_1_59_1 e_1_2_8_1_14_1 e_1_2_8_1_33_1 e_1_2_8_1_56_1 e_1_2_8_1_10_1 e_1_2_8_1_52_1 e_1_2_8_1_71_1 e_1_2_8_1_8_1 Khamis MM (e_1_2_8_1_50_1) 2018 e_1_2_8_1_102_1 e_1_2_8_1_121_1 e_1_2_8_1_106_1 e_1_2_8_1_125_1 e_1_2_8_1_86_1 e_1_2_8_1_26_1 e_1_2_8_1_49_1 e_1_2_8_1_25_1 e_1_2_8_1_44_1 e_1_2_8_1_67_1 e_1_2_8_1_21_1 e_1_2_8_1_40_1 e_1_2_8_1_63_1 e_1_2_8_1_129_1 e_1_2_8_1_113_1 e_1_2_8_1_90_1 e_1_2_8_1_132_1 e_1_2_8_1_4_1 e_1_2_8_1_94_1 e_1_2_8_1_136_1 e_1_2_8_1_75_1 e_1_2_8_1_98_1 e_1_2_8_1_18_1 e_1_2_8_1_37_1 e_1_2_8_1_79_1 e_1_2_8_1_11_1 e_1_2_8_1_57_1 e_1_2_8_1_34_1 e_1_2_8_1_53_1 e_1_2_8_1_30_1 e_1_2_8_1_9_1 e_1_2_8_1_119_1 US‐FDA (e_1_2_8_1_117_1) 2015 e_1_2_8_1_122_1 e_1_2_8_1_103_1 e_1_2_8_1_83_1 e_1_2_8_1_126_1 e_1_2_8_1_87_1 e_1_2_8_1_27_1 e_1_2_8_1_22_1 e_1_2_8_1_68_1 e_1_2_8_1_45_1 e_1_2_8_1_64_1 e_1_2_8_1_41_1 e_1_2_8_1_60_1 e_1_2_8_1_107_1 e_1_2_8_1_110_1 e_1_2_8_1_133_1 e_1_2_8_1_91_1 US‐FDA (e_1_2_8_1_118_1) 2018 e_1_2_8_1_114_1 e_1_2_8_1_137_1 e_1_2_8_1_5_1 e_1_2_8_1_72_1 e_1_2_8_1_95_1 e_1_2_8_1_19_1 e_1_2_8_1_76_1 e_1_2_8_1_15_1 e_1_2_8_1_99_1 e_1_2_8_1_38_1 e_1_2_8_1_12_1 e_1_2_8_1_35_1 e_1_2_8_1_31_1 e_1_2_8_1_54_1 Nobakht M. Gh BF (e_1_2_8_1_82_1) 2014 e_1_2_8_1_100_1 e_1_2_8_1_123_1 e_1_2_8_1_80_1 e_1_2_8_1_127_1 e_1_2_8_1_104_1 e_1_2_8_1_84_1 e_1_2_8_1_88_1 e_1_2_8_1_28_1 e_1_2_8_1_23_1 e_1_2_8_1_46_1 e_1_2_8_1_69_1 e_1_2_8_1_42_1 e_1_2_8_1_65_1 e_1_2_8_1_61_1 e_1_2_8_1_108_1 e_1_2_8_1_2_1 e_1_2_8_1_134_1 e_1_2_8_1_111_1 e_1_2_8_1_6_1 e_1_2_8_1_92_1 e_1_2_8_1_138_1 e_1_2_8_1_115_1 e_1_2_8_1_73_1 Milošev I (e_1_2_8_1_78_1) 2013; 60 e_1_2_8_1_96_1 e_1_2_8_1_16_1 e_1_2_8_1_39_1 e_1_2_8_1_77_1 e_1_2_8_1_130_1 |
| References_xml | – ident: e_1_2_8_1_79_1 doi: 10.1373/clinchem.2003.025478 – ident: e_1_2_8_1_86_1 doi: 10.1016/j.aca.2013.07.045 – ident: e_1_2_8_1_55_1 doi: 10.1016/j.cca.2015.04.005 – ident: e_1_2_8_1_21_1 – volume-title: Food and Drug Administration, FDA guidance for industry:bioanalytical method validation, DRAFT GUIDANCE year: 2018 ident: e_1_2_8_1_118_1 – volume: 132 start-page: 119 year: 2003 ident: e_1_2_8_1_58_1 article-title: Validation of assays for the bioanalysis of novel biomarkers: Practical recommendations for clinical investigation of new drug entities publication-title: Drugs Pharm Sci – ident: e_1_2_8_1_60_1 doi: 10.1007/s00216-011-5439-8 – ident: e_1_2_8_1_62_1 doi: 10.1074/jbc.R111.238691 – ident: e_1_2_8_1_48_1 doi: 10.1016/j.aca.2017.08.007 – ident: e_1_2_8_1_64_1 doi: 10.1007/s00726-016-2212-5 – ident: e_1_2_8_1_103_1 doi: 10.1258/acb.2010.009270 – ident: e_1_2_8_1_15_1 doi: 10.1007/s00467-008-0756-7 – ident: e_1_2_8_1_2_1 doi: 10.1007/s11306-007-0091-1 – ident: e_1_2_8_1_13_1 doi: 10.1002/bmc.703 – ident: e_1_2_8_1_7_1 doi: 10.1373/clinchem.2004.039701 – ident: e_1_2_8_1_20_1 – ident: e_1_2_8_1_45_1 doi: 10.1039/c0mb00110d – ident: e_1_2_8_1_131_1 doi: 10.1021/ac3025625 – volume-title: Food and Drug Administration, FDA guidance for industry: analytical procedures and methods validation for drugs and biologics year: 2015 ident: e_1_2_8_1_117_1 – ident: e_1_2_8_1_34_1 doi: 10.1021/ac900166a – ident: e_1_2_8_1_83_1 doi: 10.1016/j.jpba.2015.02.040 – ident: e_1_2_8_1_128_1 doi: 10.1093/nar/gkn810 – ident: e_1_2_8_1_95_1 doi: 10.1002/bmc.329 – ident: e_1_2_8_1_98_1 doi: 10.1016/j.jchromb.2006.02.016 – ident: e_1_2_8_1_113_1 – ident: e_1_2_8_1_43_1 doi: 10.1021/ac060920l – ident: e_1_2_8_1_109_1 doi: 10.1016/j.jpba.2016.06.017 – ident: e_1_2_8_1_11_1 doi: 10.1373/49.7.1041 – ident: e_1_2_8_1_77_1 doi: 10.2174/1874467211205020301 – ident: e_1_2_8_1_85_1 doi: 10.1016/j.talanta.2011.01.003 – ident: e_1_2_8_1_36_1 doi: 10.1016/j.chroma.2010.11.047 – ident: e_1_2_8_1_49_1 doi: 10.1002/mas.21455 – ident: e_1_2_8_1_112_1 doi: 10.1016/j.jpba.2012.04.018 – ident: e_1_2_8_1_6_1 – ident: e_1_2_8_1_9_1 doi: 10.1016/j.trac.2009.12.003 – ident: e_1_2_8_1_61_1 doi: 10.1002/rcm.1400 – ident: e_1_2_8_1_94_1 doi: 10.1016/j.jchromb.2009.09.038 – ident: e_1_2_8_1_80_1 doi: 10.1002/mas.20097 – ident: e_1_2_8_1_17_1 doi: 10.1002/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO;2-0 – ident: e_1_2_8_1_69_1 doi: 10.1038/srep21433 – ident: e_1_2_8_1_75_1 doi: 10.1002/rcm.876 – ident: e_1_2_8_1_23_1 doi: 10.1002/mas.20108 – ident: e_1_2_8_1_18_1 doi: 10.1016/j.chroma.2013.03.072 – ident: e_1_2_8_1_10_1 – ident: e_1_2_8_1_22_1 doi: 10.1016/S0378-4347(01)00552-7 – ident: e_1_2_8_1_130_1 doi: 10.1016/j.aca.2009.06.033 – ident: e_1_2_8_1_124_1 doi: 10.1074/mcp.M111.016006 – ident: e_1_2_8_1_127_1 doi: 10.1093/nar/gks1065 – year: 2018 ident: e_1_2_8_1_50_1 article-title: Quantitative determination of potential urine biomarkers of respiratory illnesses using new targeted metabolomic approach publication-title: Anal Chim Acta – ident: e_1_2_8_1_136_1 doi: 10.1021/ac050697c – ident: e_1_2_8_1_92_1 doi: 10.1016/j.aca.2010.10.035 – ident: e_1_2_8_1_121_1 doi: 10.1016/j.cca.2011.09.007 – ident: e_1_2_8_1_81_1 doi: 10.1016/j.jpba.2006.09.030 – ident: e_1_2_8_1_129_1 doi: 10.1016/j.cca.2008.10.014 – ident: e_1_2_8_1_133_1 doi: 10.1016/j.trac.2011.08.009 – ident: e_1_2_8_1_108_1 doi: 10.1016/j.clinbiochem.2004.11.007 – ident: e_1_2_8_1_70_1 doi: 10.1016/j.aca.2013.06.044 – ident: e_1_2_8_1_25_1 doi: 10.1039/B906712B – ident: e_1_2_8_1_90_1 doi: 10.1002/rcm.4459 – ident: e_1_2_8_1_53_1 doi: 10.1021/ac049746w – ident: e_1_2_8_1_99_1 doi: 10.1038/nature07762 – ident: e_1_2_8_1_106_1 doi: 10.1016/j.jsbmb.2013.06.014 – ident: e_1_2_8_1_3_1 doi: 10.1016/j.jaci.2015.05.022 – ident: e_1_2_8_1_66_1 doi: 10.1002/rcm.1268 – ident: e_1_2_8_1_68_1 doi: 10.1021/ac5023315 – ident: e_1_2_8_1_33_1 doi: 10.1002/anie.200905579 – ident: e_1_2_8_1_35_1 doi: 10.1016/j.cca.2009.09.003 – ident: e_1_2_8_1_74_1 doi: 10.1021/ac020361s – ident: e_1_2_8_1_27_1 doi: 10.1158/1055-9965.EPI-08-0355 – ident: e_1_2_8_1_47_1 doi: 10.1007/s00726-015-2076-0 – ident: e_1_2_8_1_28_1 doi: 10.1016/j.foodchem.2011.10.064 – ident: e_1_2_8_1_89_1 doi: 10.1016/j.aca.2008.07.036 – ident: e_1_2_8_1_26_1 – ident: e_1_2_8_1_65_1 doi: 10.1021/ac034505u – ident: e_1_2_8_1_87_1 doi: 10.1016/j.jpba.2010.01.016 – ident: e_1_2_8_1_135_1 doi: 10.1007/978-1-4614-3828-1 – ident: e_1_2_8_1_42_1 doi: 10.1016/S0021-9673(01)01429-7 – ident: e_1_2_8_1_134_1 doi: 10.1002/mas.20316 – ident: e_1_2_8_1_29_1 doi: 10.1016/j.jchromb.2014.09.032 – ident: e_1_2_8_1_38_1 doi: 10.1016/j.chroma.2015.12.031 – ident: e_1_2_8_1_91_1 doi: 10.1002/0471142727.mb3002s98 – ident: e_1_2_8_1_100_1 doi: 10.1016/j.jchromb.2013.10.005 – ident: e_1_2_8_1_120_1 doi: 10.1016/j.jchromb.2010.03.035 – ident: e_1_2_8_1_96_1 doi: 10.4155/bio.12.218 – ident: e_1_2_8_1_110_1 doi: 10.1002/mas.20306 – ident: e_1_2_8_1_88_1 – ident: e_1_2_8_1_138_1 doi: 10.1016/j.cca.2009.11.003 – ident: e_1_2_8_1_122_1 doi: 10.1016/j.jpba.2006.08.010 – ident: e_1_2_8_1_57_1 doi: 10.1007/s11095-005-9045-3 – ident: e_1_2_8_1_119_1 doi: 10.1016/j.trac.2008.09.002 – ident: e_1_2_8_1_31_1 doi: 10.1016/j.chroma.2009.11.060 – ident: e_1_2_8_1_126_1 doi: 10.1016/j.jpba.2011.05.009 – ident: e_1_2_8_1_123_1 doi: 10.1016/j.chroma.2013.09.085 – ident: e_1_2_8_1_104_1 doi: 10.1002/rcm.2640 – ident: e_1_2_8_1_105_1 doi: 10.1155/2002/212987 – start-page: 1 year: 2014 ident: e_1_2_8_1_82_1 article-title: The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis publication-title: Biomarkers – ident: e_1_2_8_1_125_1 doi: 10.1016/j.jchromb.2009.01.007 – ident: e_1_2_8_1_52_1 doi: 10.1007/s00216-018-1205-5 – ident: e_1_2_8_1_137_1 doi: 10.1021/acs.analchem.6b02967 – ident: e_1_2_8_1_46_1 doi: 10.1021/ac1019914 – volume: 60 start-page: 543 year: 2013 ident: e_1_2_8_1_78_1 article-title: The effect of fluoride ions on the corrosion behaviour of Ti metal, and Ti6–Al–7Nb and Ti–6Al–4V alloys in artificial saliva publication-title: Acta Chim Slov – ident: e_1_2_8_1_67_1 doi: 10.1016/j.jchromb.2007.12.011 – ident: e_1_2_8_1_73_1 doi: 10.1007/s00204-010-0609-6 – ident: e_1_2_8_1_76_1 doi: 10.2337/db13-0570 – ident: e_1_2_8_1_5_1 doi: 10.1016/j.jsbmb.2004.10.015 – ident: e_1_2_8_1_51_1 doi: 10.1007/s11306-018-1418-9 – ident: e_1_2_8_1_54_1 doi: 10.1016/j.ab.2007.03.018 – ident: e_1_2_8_1_56_1 doi: 10.1002/rcm.1243 – ident: e_1_2_8_1_14_1 doi: 10.1007/s11306-011-0342-z – ident: e_1_2_8_1_19_1 doi: 10.1007/s00216-012-6375-y – ident: e_1_2_8_1_107_1 doi: 10.1016/j.jchromb.2009.08.019 – ident: e_1_2_8_1_59_1 doi: 10.1007/s11095-005-2495-9 – ident: e_1_2_8_1_44_1 doi: 10.1002/rcm.1112 – ident: e_1_2_8_1_102_1 doi: 10.1002/rcm.1790 – ident: e_1_2_8_1_40_1 – ident: e_1_2_8_1_37_1 doi: 10.2217/bmm.09.81 – ident: e_1_2_8_1_12_1 doi: 10.1016/j.jchromb.2019.05.021 – ident: e_1_2_8_1_93_1 doi: 10.1002/rcm.617 – ident: e_1_2_8_1_32_1 doi: 10.2217/14622416.7.7.1095 – ident: e_1_2_8_1_41_1 doi: 10.1371/journal.pmed.0020124 – ident: e_1_2_8_1_115_1 doi: 10.1021/ja036006g – ident: e_1_2_8_1_4_1 doi: 10.1378/chest.11-2028 – ident: e_1_2_8_1_8_1 doi: 10.1128/AEM.03595-14 – ident: e_1_2_8_1_16_1 doi: 10.1016/j.chroma.2011.10.081 – ident: e_1_2_8_1_72_1 doi: 10.1002/jms.3536 – ident: e_1_2_8_1_111_1 doi: 10.4103/2229-4708.72226 – ident: e_1_2_8_1_30_1 doi: 10.1016/j.jpba.2013.06.032 – ident: e_1_2_8_1_63_1 doi: 10.1016/S0003-2670(03)00463-X – ident: e_1_2_8_1_116_1 doi: 10.1667/RR1703.1 – ident: e_1_2_8_1_39_1 doi: 10.1016/j.chroma.2016.02.009 – ident: e_1_2_8_1_132_1 doi: 10.1002/rcm.1530 – ident: e_1_2_8_1_71_1 doi: 10.1002/rcm.3755 – ident: e_1_2_8_1_114_1 doi: 10.1002/mas.20298 – ident: e_1_2_8_1_84_1 doi: 10.1002/rcm.2787 – ident: e_1_2_8_1_97_1 doi: 10.1039/b209521c – ident: e_1_2_8_1_24_1 doi: 10.1039/a805224g – ident: e_1_2_8_1_101_1 doi: 10.1016/j.aca.2012.05.006 |
| SSID | ssj0011511 |
| Score | 2.5457249 |
| SecondaryResourceType | review_article |
| Snippet | Metabolomics is a dynamically evolving field, with a major application in identifying biomarkers for drug development and personalized medicine. Numerous... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 31 |
| SubjectTerms | Biomarkers blank matrix Drug development endogenous biomarkers internal standards LC‐MS/MS Liquid chromatography Mass spectroscopy Metabolites Metabolomics Precision medicine validation |
| Title | STRATEGIES AND CHALLENGES IN METHOD DEVELOPMENT AND VALIDATION FOR THE ABSOLUTE QUANTIFICATION OF ENDOGENOUS BIOMARKER METABOLITES USING LIQUID CHROMATOGRAPHY‐TANDEM MASS SPECTROMETRY |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmas.21607 https://www.ncbi.nlm.nih.gov/pubmed/31617245 https://www.proquest.com/docview/2469834987 https://www.proquest.com/docview/2306220915 |
| Volume | 40 |
| WOSCitedRecordID | wos000490133000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1098-2787 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011511 issn: 0277-7037 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj5RAEO7sQxMvvnVH101rPOwFFxoYIJ6YoXlEBkYem9kTgYZOTNZZs7Pr2Z_g3_Hv-Eusbhh0oyYmnoBUQRO6quurbro-hF4bjEPmoxmKA8FWMTgkKI3lcIVD9G4cu-0ItyXZhJUk9mrlLHfQ2-1emL4-xDjhJjxDjtfCwetmc_KzaOjHevOGiPJou2hfbKqCzGvfy_wyHhcRIJhJwjyxSgmGbW0LC6nkZLz5Zjj6DWPehKwy5vj3_utt76O7A9TEbm8bD9BOt36IbstfPtnmEfom6JILGgAexG7i4XnoxjFNAriMErygRZh6-BeOTql06saRJ6e1MKSPuAgpdmd5GpcFxQCOkyLyh63JOPUxTbw0oEla5ngWpQs3e0cz8WR3lsYwZOZYkH4EOI7el5F4gQx0ijTI3GV49v3L1wJapAu8cPMc50s6L0BOi-zsMSp9WsxDZSByUJhu6pbSmUSd8pqpbcs6GEE0q2Fmqztcre3OtJjTqNxsG8AuAr2qvDa7loM2JK-dZk8b_QnaW1-suwOEp4wwh7Sa7bSawdm0JmCCXGUqhyNxyAQdb_uzYkOVc0G2cV719ZlJBT1RyZ6YoFej6qe-tMeflA63RlEN3g0SQbupG44N4pejGPxSLLbU6-7iGnQgFyME0Jg5QU97Yxpb0UVSSQyQHEub-XvzFXxiefLs31WfoztE_Hgj54kO0d7V5XX3At1in68-bC6P0K61so8GV_kBvEEI0w |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELbKFgQX_n8WChjEoZfQxPmXuGR3vZuo2WRJHNSeosSJpUpli7otZx6B1-F1eBLGTjZQARISpySaSWzFM55vxvYMQm8sLsDzMSzNB2OrWQIclNr1hSbAete-17REeKrYhJsk3tGRv9pB77ZnYbr8EEPATWqGmq-lgsuA9MHPrKEfq81bIvOjXUO7lmO63gjtzrJ5EQ-rCGDNVMU8uUwJku1uMwvp5GB4-ao9-g1kXsWsyujM7_xfd--i2z3YxEEnHffQTru-j26oTZ988wB9kwWTGV0AIsRBMsPTMIhjmizgMUrwkrIwneFfqnQqpg9BHM1UYAuDA4lZSHEwydO4YBQDPE5YNO8PJ-N0jmkySxc0SYscT6J0GWSHNJNfDiZpDJNmjmXZjwWOo_dFJDuQAQ9LF1mwCo-_f_nKoEW6xMsgz3G-olMGdMqy44eomFM2DbW-lIPGTdt0tdYmuiMqrjcNb2EOMdya243pC73yWtvlfq0Lu6kBvUj8qovKbhsB3OC-tobn1OYjNFqfrdsnCDuccJ80huc3hiW4UxEQQqFzXcCV-GSM9rcDWvI-z7kst3FadhmaSQkjUaqRGKPXA-unLrnHn5j2tlJR9voNFFl407R8D8ivBjJoplxuqdbt2SXwgDdGCOAxe4wed9I0tGJKt5JYQNlXQvP35kv4xerm6b-zvkQ3Q7aMyzhKDp-hW0Ruw1FRoz00uji_bJ-j6_zzxcnm_EWvMT8Aey0L2w |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELbKFhAX_n8WChjEoZfQrJNsYolLduPsRs0mS36q9hQlji0hwbbqtpx5BF6H1-FJGHuzgQqQkDgl0UxiK57xfGMn8yH0xuYSMp-RbVAItoYtIUFpXCoNCdG7oV4riPQ02YSbJN7xMV3uoHfbf2E29SH6BTflGXq-Vg4uzlp58LNq6Kd6_Zao-mjX0K7tUMceoN0gC8u430WAaKYZ89Q2JVi2u60sZJKD_uar8eg3kHkVs-qgE975v-7eRbc7sIn9jXXcQztidR_d0B998vUD9E0RJhdsBogQ-0mAp3M_jlkyg8sowQtWzNMA_8LSqZWO_DgK9MIWhgQSF3OG_UmexmXBMMDjpIjC7udknIaYJUE6Y0la5ngSpQs_O2SZerI_SWOYNHOsaD9mOI7el5HqQAY6RTrL_OX85PuXrwW0yBZ44ec5zpdsWoCcFdnJQ1SGrJjOjY7KweCWY7mGcIg5ljU325YLmENGbsOd1qLSrD3huJw2pnTaBtCLwq-mrB3RStCG9FWMvHFjPUKD1elKPEF4zAmnpB15tB3Zko9rAkYoTW5KOBJKhmh_O6AV7-qcK7qNj9WmQjOpYCQqPRJD9LpXPdsU9_iT0t7WKqrOv0GiiDctm3ogftWLwTPVdku9EqeXoAPZGCGAx5wheryxpr4VS6WVxAbJvjaavzdfwSvWJ0__XfUlurkMwiqOksNn6BZRX-HoRaM9NLg4vxTP0XX--eLD-vxF5zA_AO7IC1Y |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=STRATEGIES+AND+CHALLENGES+IN+METHOD+DEVELOPMENT+AND+VALIDATION+FOR+THE+ABSOLUTE+QUANTIFICATION+OF+ENDOGENOUS+BIOMARKER+METABOLITES+USING+LIQUID+CHROMATOGRAPHY-TANDEM+MASS+SPECTROMETRY&rft.jtitle=Mass+spectrometry+reviews&rft.au=Khamis%2C+Mona+M&rft.au=Adamko%2C+Darryl+J&rft.au=El-Aneed%2C+Anas&rft.date=2021-01-01&rft.eissn=1098-2787&rft.volume=40&rft.issue=1&rft.spage=31&rft_id=info:doi/10.1002%2Fmas.21607&rft_id=info%3Apmid%2F31617245&rft.externalDocID=31617245 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0277-7037&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0277-7037&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0277-7037&client=summon |